Mucopolysaccharidosis type IVA (MPS IVA, also called Morquio syndrome, type A) is a metabolic condition that primarily affects the skeleton. The severity, age of onset, and associated symptoms vary significantly from person to person and range from a severe and rapidly progressive, early-onset form to a slowly progressive, later-onset form Life Saving Drugs Program - Mucopolysaccharidosis type IVA (MPS IVA) - Guidelines . These guidelines contain the general, initial and ongoing eligibility requirements to access treatment for mucopolysaccharidosis type IVA (MPS IVA) under the Life Saving Drugs Program
Morquio A syndrome (mucopolysaccharidosis IVA) is a lysosomal storage disorder associated with skeletal and joint abnormalities and significant non-skeletal manifestations including respiratory disease, spinal cord compression, cardiac disease, impaired vision, hearing loss, and dental problems. The Mucopolysaccharidosis type IVA (MPS IVA) or Morquio syndrome is a multisystem disorder caused by galactosamine-6-sulfatase deficiency. Skeletal manifestations, including short stature, skeletal dysplasia, cervical instability, and joint destruction, are known to be associated with this condition. Du Recommendations for the management of MPS IVA: Systematic evidence- A nd consensus-based guidanc The initial guidelines address the diagnosis of MPS IVA, which is beyond the scope of this paper. The final section of the guidelines address the management of this disorder. ERT is recommended as soon as the diagnosis has been confirmed as this treatment has shown effective in improving endurance and respiratory function
The results of the modified-Delphi voting process are described in more detail in the companion publication (Recommendations for the management of MPS IVA: systematic evidence- and consensus-based guidance).After two rounds of anonymised voting via an online survey (from a pool of 197 MPS physicians across 35 clinical areas of focus in 25 countries worldwide), consensus was reached on 94. Hendriksz CJ et al. International guidelines for the management and treatment of Morquio A syndrome. Am J Med Genet 2015;167A(1):11-25. Akyol MU et al. Recommendations for the management of MPS IVA: systematic evidence- and consensus-based guidance
MPS IVA is an autosomal recessive genetic disorder caused by deficiency of the GALNS enzyme due to mutations in the GALNS gene.. MPS IVB is an autosomal recessive genetic disorder caused by deficiency of the beta-galactosidase enzyme due to mutations in the GLB1 gene.. Both lead to an accumulation of keratan sulfate (KS) in the cells and tissues of the body Enzyme replacement therapy (ERT) is approved in the United States, European Union, and several other countries for patients with MPS I, MPS II, MPS IVA, MPS VI, and MPS VII . Indications vary across the MPS, but generally ERT is used in patients with moderate-to-severe disease or clinical complications
lysosomal storage disorder called mucopolysaccharidosis (MPS) IVA (Morquio A syndrome). This guidelines is also subject to CG-DRUG-47 (Level Of Care: Specialty Pharmaceuticals). Administered by AIM. • CG-DRUG-56 Galsulfase (Naglazyme ®): This document addresses the clinical indications for galsulfas The phenotypic spectrum of mucopolysaccharidosis IVA (MPS IVA) is a continuum that ranges from a severe and rapidly progressive early-onset form to a slowly progressive later-onset form. Children with MPS IVA have no distinctive clinical findings at birth. The severe form is usually apparent between ages one and three years, often first manifesting as kyphoscoliosis, knock-knee (genu valgum. Morquio A syndrome (mucopolysaccharidosis [MPS] IVA, OMIM #253000) is a lysosomal storage disorder (LSD) inherited in an autosomal recessive fashion. It is caused by a deficiency in the enzyme N-acetylgalactosamine-6-sulfatase (GALNS) due to a mutation in the GALNS gene located on chromosome 16q24.3 Mucopolysaccharidosis type IVA (MPS IVA) or Morquio syndrome is a multisystem disorder caused by galactosamine-6-sulfatase deficiency. Skeletal manifestations, including short stature, skeletal dysplasia, cervical instability, and joint destruction, are known to be associated with this condition Mucopolysaccharidosis type IV (MPS IV), also known as Morquio syndrome, is a progressive condition that mainly affects the skeleton. The rate at which symptoms worsen varies among affected individuals. The first signs and symptoms of MPS IV usually become apparent during early childhood. Affected individuals develop various skeletal.
Join us to learn about the natural history of MPS IVA (Morquio A syndrome) and the long-term impact of treatment with elosulfase alfa, the only approved enzyme replacement therapy for this progressive and multisystemic disorder. EU-MPSIV-00017. Date of preparation: June 2021 An MPS diagnosis is based on laboratory results from urinary GAG analyses and enzyme activity assays. Enzyme activity assays measure enzyme activity in tissue (blood or fibroblasts). Quantitative GAG assays measure overall elevation of GAG as compared with GAG levels expected in age-matched normal subjects COVERAGE GUIDELINES The plan may authorize coverage of Vimizim (elosulfase alfa) for Members when all the following criteria are met: 1. Documented diagnosis of Mucopolysaccharidosis type IV A (MPS IVA; Morquio A syndrome) disease by a specialist AND 2. Member is at least 5 years of age LIMITATION
Overview. Mucopolysaccharidosis type IVA (MPS IVA, also called Morquio syndrome, type A) is a metabolic condition that primarily affects the skeleton. The severity, age of onset, and associated symptoms vary significantly from person to person and range from a severe and rapidly progressive, early-onset form to a slowly progressive, later-onset form Mucopolysaccharidosis IVA (MPS IVA), also known as Morquio A, is a rare, autosomal recessive disorder caused by a deficiency of the lysosomal enzyme N-acetylgalatosamine-6-sulfate-sulfatase (GALNS), which catalyzes a step in the catabolism of glycosaminoglycans (GAGs), keratan sulfate (KS) and chondroitin-6-sulfate (C6S) Enzyme replacement therapies are currently in use for MPS I, MPS II, MPS IVA, MPS VI, and MPS VII, and are being tested in other MPS disorders. Enzyme replacement therapy involves an intravenous solution containing an enzyme that is deficient or missing from the body. It does not cure the neurological manifestations of the disease but has.
Coverage may be provided with a diagnosis of Mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome) and the following criteria is met: Member is 5 years of age or older. recognized compendia, and/or evidence-based practice guidelines Guidelines for the evaluation and management of spinal cord compression in patients with MPS VI and IVA were published in 2012 and 2013, respectively , . Recently, a group of experts also published consensus recommendations for the early identification and management of spinal cord compression in MPS IVA patients, including a list of routine. Introduction. Morquio A syndrome, or mucopolysaccharidosis IVA (MPS IVA), is an autosomal recessive lysosomal storage disorder caused by defective activity of N-acetyl-galactosamine-6-sulfatase (GALNS), an enzyme that catabolizes the glycosaminoglycans keratan sulfate and chondroitin-6-sulfate.Symptoms typically become apparent during the first few months or years of life, as intracellular.
.g. chest. Holzgreve W, Gröbe H, von Figura K, et al. Morquio syndrome: clinical findings in 11 patients with MPS IVA and 2 patients with MPS IVB. Hum Genet 1981; 57:360. Stevens JM, Kendall BE, Crockard HA, Ransford A
Mucopolysaccharidosis type IVA (MPS IVA, or Morquio syndrome type A) is an inherited metabolic lysosomal disease caused by the deficiency of the N-acetylglucosamine-6-sulfate sulfatase enzyme. The deficiency of this enzyme accumulates the specific glycosaminoglycans (GAG), keratan sulfate, and chondroitin-6-sulfate mainly in bone, cartilage, and its extracellular matrix years of age or older with a documented diagnosis of mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome) defined as meeting ALL of the following criteria: • Documented clinical signs and symptoms of the disease (e.g., kyphoscoliosis, corneal opacity, genu valgum, pectus carinatum, gait disturbance, growth deficiency); an
Background: Mucopolysaccharidosis IVA (MPS IVA; Morquio A syndrome) is a rare autosomal recessive lysosomal storage disorder. Up to now, reports on the clinical characteristics of MPS IVA mainly focused on patients with progressive bone dysplasia and multiple organ damage, while the effects of this disorder on neurogenic bladder have not been. The Objective Mucopolysaccharidosis IVA (MPS IVA, or records of 5 MPS IVA and 3 MPS VI patients with delayed Morquio A syndrome) and VI (MPS VI, or Maroteaux- diagnosis were reviewed. Radiographs were evaluated by a Lamy syndrome) are autosomal recessive lysosomal storage radiologist with special expertise in skeletal dysplasias. disorders
The incidence of MPS IVA ranges among various populations from 1 in 76.000 live births in Northern Ireland to 1 in 640.000 live births in Western Australia (4-6). The higher incidence for Turkey is expected because of the high incidence of consanguinity marriages however we do not have a registration system for MPS IVA patients in our country Generally, MPS IVA patients are wheelchair-bound as teenagers and do not survive beyond the second or third decade of life as a result of severe bone dysplasia, causing restrictive lung disease and airway narrowing, increasing potential for pneumonia and apnea; stenosis and instability of the upper cervical region; high risk during anesthesia. mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome). Coverage Guidelines Mucopolysaccharidosis Type IVA (MPS IVA; Morquio A Syndrome) The individual must meet . all. of the following criteria for approval: • Diagnosis is confirmed by one of the following: o Laboratory test demonstrating deficient N-acetylgalactosamine-6-sulfatas INDICATION VIMIZIM ® (elosulfase alfa) is indicated for patients with mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome).. IMPORTANT SAFETY INFORMATION. Life-threatening anaphylactic reactions have occurred in some patients during VIMIZIM infusions. Anaphylaxis, presenting as cough, erythema, throat tightness, urticaria, flushing, cyanosis, hypotension, rash, dyspnea, chest. Abstract. Mucopolysaccharidosis IV A (Morquio syndrome A, MPS IVA) is a lysosomal storage disease caused by the deficiency of N-acetylgalactosamine-6-sulfatase (GALNS). The mutation spectrum in this condition is yet to be determined in Indians. We aimed to analyze the mutations in the GALNS gene in Asian Indians with MPS IVA
ABSTRACT: Mucopolysaccharidosis IVA (MPS IVA) is a rare autosomal recessive lysosomal storage disorder resulting from N-acetylgalactosamine-6-sulfatase (GALNS) deficiency that occurs in approximately 1 in 76000 to 1 in 640 000 live births. Given that the diagnosis of MPS IVA relie Mucopolysaccharidosis IVA (MPS IVA; Morquio A), is a lysosomal storage disorder characterized by the deficiency of N-acetylgalactosamine-6-sulfatase (GALNS), resulting in the accumulation of glycosaminoglycans (GAGs) such as keratan sulfate (KS) (Northover et al., 1996) and chondroitin-6-sulfate. There is no applicable animal model or appropriate cell lines currently available for the study of. Elosulfase alfa (Vimizim) may be considered medically necessary for patients five (5) years of age or older with a documented diagnosis of mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome) defined as meeting BOTH of the following criteria:. Documented clinical signs and symptoms of the disease (e.g., kyphoscoliosis, corneal opacity, genu valgum, pectus carinatum, gait disturbance. MPS IVA has a profound impact on all parts of a patient's life, given the progressive nature of the disease and the range of sequelae of the enzyme deficiency. MPA IVA leads to hernias, chronic ear infections, hearing impairment, corneal clouding, diarrhea, hear We present 3 patients with MPS type IVA who underwent airway stenting using Montgomery ® T-tube stents. Three-dimensional reconstructed computed tomography was essential to design the T-tube and evaluate the anatomical relationship between the innominate artery and the trachea
1) An overview of the global market for Enzyme Replacement Therapy Marketand related technologies. 2) Analyses of global market trends, with data from 2015, estimates for 2016 and 2017, and. MPS IVA is a metabolic disorder in which the body lacks the enzyme needed to break down certain natural substances. These substances can build up in the body, causing enlarged organs, abnormal. MPS type IVA (Morquio A syndrome) i. MPS type IVA is a autosomal recessive lysosomal storage disorder caused by a mutation on the The American College of Medical Genetics 2011 guidelines state MPS type VI should be confirmed through serum assay showing a decrease of N-acetylgalactosamine-4 -sulfatase activity. Onc Mucopolysaccharidosis IVA (MPS IVA, or Morquio A syndrome) and VI (MPS VI, or Maroteaux-Lamy syndrome) are autosomal recessive lysosomal storage disorders. Skeletal abnormalities are common initial presenting symptoms and, when recognized early, may facilitate timely diagnosis and intervention, leading to improved patient outcomes. Patients with slowly progressing disease and nonclassic. Vimizim is an enzyme preparation for patients diagnosed withMucopolysaccharidosis type IVA (MPS IVA). Vimizim is intended to replace the missing GALNS enzyme involved in an important metabolic pathway. Anaphylaxis hasbeen reported to occur during Vimizim infusions, regardless of duration of the course of treatment
MPS type IVA in a 7-year-old girl. (a) Lateral radiograph of the cervical spine in flexion shows detachment between the anterior arch of C1 and the odontoid process, although the atlantoaxial predentate space (3 mm) Management guidelines for mucopolysaccharidosis VI Mucopolysaccharidosis type IVA (Morquio A syndrome [MPS IVA]). 1. It is produced in Chinese hamster ovary cells via recombinant DNA technology. Vimizim is a hydrolytic lysosomal enzyme which is taken up by lysosomes and hydrolyzes sulfate from the nonreduced ends of the glycosaminoglycans keratan - sulfate and chondroitin- 6-sulfate. Disease. Mucopolysaccharidosis IVA (MPS IVA) is a rare inherited metabolic disorder caused by galactosamine-6-sulfate sulfatase (GALNS) enzyme deficiency that leads to progressive lysosomal accumulation of glycosaminoglycans (GAGs). MPS IVA has a variable age of onset and variable severity Morquio A syndrome).based on clinical signs and symptoms of MPS IVA and documented reduced fibroblast or leukocyte N-acetylgalactosamine-6 sulfatase (GALNS) enzyme activity or genetic testing confirming diagnosis of MPS IVA. Aetna considers elosulfase experimental and investigational for all other indication
MPS IVA is generally diagnosed during the second year of life. Progressive skeletal and joint deformities lead to impairment in walking and daily activities, and include platyspondyly, kyphosis, scoliosis, pectus carinatum, genu valgum, long bone deformities, and joint hyperlaxity (neck, hands, fingers, hips, knees) The largest study on MPS IVA patients is a retrospective and descriptive study of 28 children; eight patients (seven of them with the cervical spine surgically fused) were difficult to intubate. Part of the intubations performed were conventional laryngoscopies using in-line stabilization with neutral head and neck position or with. Mucopolysaccharidoses. Mucopolysaccharidoses (MPS) are a group of genetic disorders that affect primarily the body's connective tissue. Connective tissue provides a support structure for the tissues and organs in our body, including bone, tendons, skin, the heart, eye and in many cases, the brain. The MPS disorders are divided into categories.
-FDA-approved indication: For patients with mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome). -FDA-approved dosage: 2 mg per kg given intravenously over a minimum range of 3.5 to 4.5 hours, based on infusion volume, once every week. Pre-treatment with antihistamines with or without antipyretics is recommended 30 to 6 As a result of ongoing consultation with local non-public school officials, MPS employs a third party vendor model to provide Title IA services to eligible students attending non-public schools. In 2017, the district released a Request for Proposals that led to the recommendation for approval of the two vendors listed below to provide.
Cause and effects of MPS IV: an overview Early and accurate diagnosis is critical to enable disease-specific intervention 1. Mucopolysaccharidosis (MPS) IV, or Morquio syndrome, is a progressive, multisystemic lysosomal storage disorder resulting from a deficiency of the enzymes N-acetylgalactosamine 6-sulfatase or β-galactosidase that are responsible for the catabolism of glycosaminoglycans. Elosulfase alfa is approved by the US Food and Drug Administration (FDA) for patients with Morquio A syndrome (mucopolysaccharidosis type IVA [MPS IVA]). A study by Hendriksz et al found evidence to suggest that long-term use of this agent is associated with partial recovery of functional abilities in these patients Surgery in MPS patients is associated with a high mortality rate. A study comprising 932 patients enrolled in the MPS I registry that underwent a total of 4,762 procedures showed 30-day risk of death/procedure and death/patient rates of 0.7 % and 4.2 % (Arn et al. 2012).Most serious anaesthetic complications occurring during surgery in MPS patients are associated with airway obstruction, with. Background: Mucopolysaccharidosis IVA (MPS IVA; Morquio A syndrome) is a rare lysosomal storage disorder caused by the deficiency of N-acetylgalactosamine-6-sulfatase, an enzyme involved in the catabolism of glycosaminoglycans, keratan sulfate and chondroitin-6-sulfate. Secondary cardiac abnormalities are common in patients with MPS of any types, with the most documented abnormalities being. This study aims to raise awareness of the need for research and appropriate guidelines for managing spinal cord issues in adult patients with mucopolysaccharidosis (MPS) and transition of these patients from pediatric to adult care. Pediatric/adult neurosurgeons, orthopedic spine surgeons, and treating physicians with expertise in metabolic disorders and spinal cord issues were invited to.
Mucopolysaccharidosis type IVA (Morquio A syndrome [MPS IVA]).1 It is produced in Chinese hamster ovary cells via recombinant DNA technology. Vimizim is a hydrolytic lysosomal enzyme which is taken up by lysosomes and hydrolyzes sulfate from the non-reduced ends of the glycosaminoglycans keratan sulfate and chondroitin-6-sulfate Morquio A syndrome, or mucopolysaccharidosis IVA (MPS IVA) is a disease in which people are missing an enzyme that is essential in the breakdown and removal of the glycosaminoglycans (GAGs) called. Mucopolysaccharidosis type I (MPS I) is an autosomal storage disease resulting from defective activity of the enzyme α-L-iduronidase (IDUA). This glycosidase is involved in the degradation of heparan sulfate and dermatan sulfate. MPS I has severe and milder phenotypic subtypes. Aim of study: This study was carried out on six newly collected MPS I patients recruited from many regions of Tunisia
MPS disorders: multisystemic, unpredictable and life threatening Variability in disease progression and presentation often delays diagnosis, making early intervention critical 2. While each subtype of MPS disorder is clinically distinct, all feature the life-limiting, progressive, multisystemic disease manifestations common to MPS disease pathology. 11 , 13,20,21 Management of patients with. Mucopolysaccharidosis Type IV is caused by inheriting faulty genes that prevents the body from producing certain enzymes. The condition is inherited in an autosomal recessive manner. Depending on the subtype of MPS Type IV, the gene and the enzyme it codes for varies: Mucopolysaccharidosis Type IVA: The gene responsible for MPS IVA is the GALNS. Mucopolysaccharidosis type I (MPS I) was a group of rare autosomal recessive disorder caused by the deficiency of the lysosomal enzyme, alpha -L -iduronidase, and the resulting accumulation of undergraded dematan sulfate and heparan sulfate. MPS I patients have a wide range of clinical presentations, that makes it difficult to predict patient phenotype which is needed for genetic counseling.
Hearing loss, seen on pure tone audiometry, was noted in 35 patients (83.3%; 5 in MPS I, 15 in MPS II, 4 in MPS IIIB, 8 in MPS IVA, and 3 in MPS VI). Specifically, 22 patients (52.4%) had mixed-type hearing loss, 9 (21.4%) had conductive hearing loss, and 4 (9.5%) had sensorineural hearing loss MPS IV is a lysosomal storage disease caused by accumulation of keratan sulfate and chondroitin-6-sulfate in various tissues. Pathogenic variants in GALNS and GLB1 lead to MPS IVA and MPS IVB, respectively. This test is indicated for any individual in whom MPS IV is suspected based on clinical o Mucopolysaccharidoses (MPS) are rare inherited disorders caused by a deficit of the lysosomal hydrolases involved in the degradation of mucopolysaccharides, also known as glycosaminoglycans (GAGs). They are all monogenic defects, transmitted in an autosomal recessive way, except for MPS type II which is X-linked. The enzymatic deficit causes a pathologic accumulation of undegraded or partially. Combining KS and C6S data, discriminated patients with MPS IVA from age-matched control subjects were better than either C6S or KS levels alone. In conclusion, this first report showing that blood levels of C6S are quantitatively evaluated in patients with MPS IVA and VII indicates that C6S could be a useful biomarker for these metabolic disorders
Mucopolysaccharidosis IVA (MPS IVA, Morquio A syndrome) is an autosomal recessive disorder characterized by the deficiency of the lysosomal enzyme N-acetylgalactosamine-6-sulfate sulfatase (GALNS).Deficiency of this enzyme results in accumulation of the glycosaminoglycans (GAGs), keratan sulfate (KS), and chondroitin-6-sulfate (C6S) in lysosomes of tissues  Elosulfase alfa is a purified human enzyme produced by recombinant DNA technology. It is used for enzyme replacement therapy for individuals with mucopolysaccharidosis IVA (MPS IVA, Morquio A syndrome). Mucopolysaccharidoses are a group of lysosomal storage disorders caused by the deficiency of specific enzymes required for the catabolism of. Morquio syndrome or MPS IVA is a rare type of lysosomal storage disease associated with highly specific dental abnormalities. We present two siblings with enamel hypoplasia and skeletal abnormalities. A diagnosis of mucopolysaccharidosis type IVA was reached based on the clinical, radiographic, and dental findings of the patients. The dental findings are useful diagnostic aid for the early.
Mucopolysaccharidosis IVA (MPS IVA) Indefinite authorization may be granted for treatment of MPS IVA when the diagnosis of MPS IVA was confirmed by enzyme assay demonstrating a deficiency of N-acetylgalactosamine 6-sulfatase enzyme activity or by genetic testing. D. CONTINUATION OF THERAP What is MPS IV (Morquio syndrome)? Morquio syndrome is a rare inherited genetic disease that is in a group of diseases known as mucopolysaccharidosis (MPS) syndromes. Morquio syndrome is a storage deficiency within the cells of the body, and individuals with Morquio syndrome lack specific enzymes necessary for the breakdown of specific.
Mucopolysaccharidoses (MPS) comprise a group of lysosomal disorders that are characterized by progressive, systemic clinical manifestations and a coarse phenotype. The different types, having clinical, biochemical, and genetic heterogeneity, share key clinical features in varying combinations, including joint and skeletal dysplasia, coarse facial features, corneal clouding, inguinal or. Mucopolysaccharidoses (MPSs) are a group of uncommon genetic diseases of connective tissue metabolism. It is well established that the elective treatment of subjects affected by MPS is multidisciplinary and must be carried out by experienced personnel in highly specialist centers. However, there is the possibility to perform an anesthesia in a peripheral center, where anesthesiologists might. The study tests for 4 of the types of MPS: I, II, IVA, and VI. This can help researchers decide whether to create a screening program for MPS at pediatric rheumatology clinics. This study is being done in rheumatology clinics because the first symptoms of MPS are often joint problems such as stiff joints, and rheumatologists may be the first. Mucopolysaccharidoses is a family of metabolic disorders caused by the absence or irregular functioning of lysosomal enzymes required to degrade glycosaminoglycans. Mucopolysaccharidosis IVA (MPS IVA or Morquio A syndrome) is characterized by the functional loss of the enzyme N-‐acetylgalactosamine-‐6-‐ sulfatase (GALNS). The absence of GALNS leads to the chronic accumulation of. Of the 67 patients, 13 had MPS I, 25 had MPS II, 11 had MPS IIIB, 12 had MPS IVA, and six had MPS VI, according to their clinical manifestations and symptoms, leukocyte enzyme activities, and.
Morquio B disease (MBD) is an autosomal recessive GLB1-gene-related lysosomal storage disease, presenting with a peculiar type of dysostosis multiplex which is also observed in GALNS-related Morquio A disease. MBD may present as pure skeletal phenotype (pure MBD) or in combination with the neuronopathic manifestations seen in type 2 (juvenile) or type 3 (late onset) GM1 gangliosidosis (MBD. Patients with MPS IVA have an absence or marked reduction of GALNS activity, which leads to the accumulation of the glycosaminoglycan (GAG) substrates keratan sulfate (KS) and chondroitin-6-sulfate (C6S). Patients experience widespread tissue and organ damage, but the course of progression and severity is variable Morquio A syndrome, or mucopolysaccharidosis IVA (MPS IVA) is a disease in which people are missing an enzyme that is essential in the breakdown and removal of the glycosaminoglycans (GAGs) called keratan sulfate (KS) and chondroitin-6-sulfate (C6S). The incompletely broken down GAGs remain stored in cells in the body causing progressive damage MPS VI and VII ( 253220) were more rare and accounted for 1.7% and 1.3%, respectively. A retrospective epidemiologic data collection was performed in Switzerland between 1975 and 2008 (34 years), and 41 living MPS patients were identified. The combined birth prevalence was 1.56 per 100,000 live births ients who may benefit from specific treatments. The aim of this prospective study was to assess a novel selective screening program, the FIND project, targeting patients aged 0 to 16 years with clinical manifestations of MPS. The project was designed to increase awareness of these diseases among pediatricians and allow early diagnosis. From July 2014 to June 2016, glycosaminoglycan (GAG. Mucopolysaccharidosis type III (MPS III) comprises a group of rare lysosomal storage diseases. Although musculoskeletal symptoms are less pronounced than in other MPS subtypes, pathologies of hip and spine have been reported in MPS III patients. The purpose of this study was to describe hip pathologies and influencing parameters in MPS III patients